Strube W, Auer S, Block W, Heinen E, Kretzdorn D, Rodenbach C, Schmeer N
Bayer AG, Institute of Infectious Diseases, Leverkusen, Germany.
Vet Microbiol. 1996 Nov;53(1-2):181-9. doi: 10.1016/s0378-1135(96)01246-1.
Based on a glycoprotein E (gE) deleted bovine herpesvirus 1 (BHV1) strain (Kaashoek et al., 1994) a killed virus as well as a modified live virus marker vaccine have been developed that allow differentiation between immunized and BHV1 infected cattle. Safety and efficacy of both vaccines were tested extensively following the current European Union (EU) requirements for the development of bovine vaccines. The minimum vaccine dose, vaccination regimen, route of administration and duration of immunity were evaluated for both vaccines in comprehensive vaccination/challenge trials in cattle. The most potent adjuvant formulation for the killed virus vaccine was also selected by experimental challenge infections. For the modified live virus marker vaccine it could be demonstrated that maternally derived BHV1 specific antibodies did not interfere with vaccination. Safety could be demonstrated for both the killed virus and the modified live virus vaccine in all target animal categories including veal calves, beef cattle, bulls, heifers and dairy cattle, including pregnant animals.
基于一种缺失糖蛋白E（gE）的牛疱疹病毒1型（BHV1）毒株（Kaashoek等人，1994年），已研发出一种灭活病毒疫苗以及一种标记活疫苗，可区分免疫牛和感染BHV1的牛。两种疫苗的安全性和有效性均按照欧盟目前关于牛用疫苗研发的要求进行了广泛测试。在牛的全面疫苗接种/攻毒试验中，对两种疫苗的最小疫苗剂量、接种方案、给药途径和免疫持续时间进行了评估。通过实验性攻毒感染也为灭活病毒疫苗选择了最有效的佐剂配方。对于标记活疫苗，可以证明母源BHV1特异性抗体不会干扰疫苗接种。在包括犊牛、肉牛、公牛、小母牛和奶牛（包括怀孕动物）在内的所有目标动物类别中，均可证明灭活病毒疫苗和标记活疫苗的安全性。
